Petlife Pharmaceuticals, Inc. announced that it expects to receive $4 million in funding

PetLife Pharmaceuticals, Inc. is a veterinary pharmaceutical company. The Company specializes in the research, development, sales and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis. The Company has developed and is launching veterinary cancer medications and nutraceuticals, based on the Escozine formula. The Company has rights to formulate, package and market a product line, Vitalzul. Vitalzul is a polarized, bioactive peptide extracted from the Blue Caribbean Scorpion (Rhopularus Princeps), which contains amino acids, proteins and minerals. Vitalzul inhibits blood vessels formation in solid tumors. Escozine has been used in combination with chemotherapy, radiation, hormone therapy and other conventional treatments. As of August 31, 2016, Escozine (for humans) was sold as either a nutraceutical or prescription drug in 40 countries, including the United States.